Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy

Amyloid

Volumn 19, Issue SUPPL. 1, 2012, Pages 50-52

  Jono, Hirofumi ^a   Anno, Takayuki ^a   Motoyama, Keiichi ^a   Misumi, Yohei ^b   Tasaki, Masayoshi ^a   Oshima, Toshinori ^a   Mori, Yoshimasa ^a   Mizuguchi, Mineyuki ^c   Ueda, Mitsuharu ^a   Shinriki, Satoru ^a   Shono, Makoto ^a   Obayashi, Konen ^a   Arima, Hidetoshi ^a   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cyclodextrin; Familial amyloidotic polyneuropathy; Protein misfolding; transthyretin

Indexed keywords

6 O ALPHA (4 O ALPHA DEXTRO GLUCURONYL) DEXTRO GLUCOSYL BETA CYD (GUG BETA CYD); AMINO ACID; AMYLOID; AMYLOID PROTEIN; CYCLODEXTRIN; OLIGOSACCHARIDE; PREALBUMIN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONFORMATION; CONTROLLED STUDY; FAMILIAL AMYLOID POLYNEUROPATHY; FLUORESCENCE; HUMAN; HYDROPHOBICITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; HUMANS; MODELS, THEORETICAL; OLIGOSACCHARIDES; PREALBUMIN; PROTEIN FOLDING; RATS; RATS, TRANSGENIC;

EID: 84861436049     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.674988     Document Type: Conference Paper

References (8)

1. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062. (Pubitemid 41043725)
2. Sousa MM, Saraiva MJ. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol 2003;71:385-400. (Pubitemid 38125193)
3. Quintas A, Saraiva MJ, Brito RM. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 1999;274:32943-32949. (Pubitemid 129535333)
4. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001;293:2459-2462. (Pubitemid 32917328)
5. Uekama K, Hirayama F, Irie T. Cyclodextrin Drug Carrier Systems. Chem Rev 1998;98:2045-2076. (Pubitemid 128633447)
6. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3: 1023-1035. (Pubitemid 39642365)
7. Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 2004;21:2369-2376. (Pubitemid 40568453)
8. Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, et al. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochem J 2011;437:35-42.